Lexaria's strategy is to continue developing and optimizing our wholly-owned DehydraTECH™ drug delivery platform for application in the GLP-1 space, positioning it as a 'must-have' technology for ...

Earlier this month, Korro Bio announced a collaboration with Novo Nordisk (NYSE:NVO) to develop a pair of therapeutic ...

The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat ...

Some other companies using ADAR enzymes to perform RNA editing are Korro Bio for AATD and Parkinson’s disease ... from large ...

Based on the one-year price targets offered by 24 analysts, the average target price for Novo Nordisk AS (OCSE:NOVO B) is $957 with a high estimate of $1150 and a low estimate of $560. The average ...

Novo Nordisk's blockbuster drugs Ozempic and Wegovy have slimmed down Hollywood stars and millions of non-celebrities worldwide — all while adding great heft to Denmark's economy. Novo Nordisk ...

This week, 60 Minutes traveled to Denmark to report on Novo Nordisk, the pharmaceutical company that's behind the popular drugs Wegovy and Ozempic. Novo Nordisk's success with these drugs has led ...

Novo Nordisk, after mulling the implications of a phase 3 fail, has given up on a late-stage kidney drug acquired in a $1.3 billion deal. The Danish pharma bought the nonsteroidal ...

Novo Nordisk remains a sell due to increased competition and regulatory risks, despite its leadership in the diabetes and weight-loss markets. Hims & Hers anticipates selling a generic version of ...

Novo Nordisk was a pioneer in developing GLP-1 drugs for metabolic disorders, but its products are still mainly once-weekly injections. The Danish pharmaceutical giant is putting up $285 million ...